Em Array - Interactive Meeting Technology

Introducing ARRAY OnQ
iPad technology and on-site service that bring
increased engagement, more participation
and a whole new “Wow Factor” to your events.

ARRAY OnQ runs on its
own private network
and server, so you won’t
need to worry about
unreliable and expensive
hotel or venue Wi-Fi
service. With ARRAY OnQ
there are no issues with
connectivity and all data
and content are secure.
The data collected using
ARRAY OnQ goes into
our highly powerful
and user-friendly data
analysis software. You
can filter data sets, look
at all your programming
or focus on one meeting
and evaluate impact.
The system also creates
a summary by slide of
notes taken, questions
asked, and slide rating.
For over 10 years, EM has
provided on-site technical
service at over 5,000
events ranging in size from
10 people to 1,000.
We get it.
Welcome to ARRAY OnQ.
Companies are being asked to improve interaction at their live events and collect
quality data points to measure impact. Educational Measures developed ARRAY
for this reason and we stand apart from our competitors because:
About EM
We develop and deploy event
technolgies and top-end service
for a wide variety of industries.

ARRAY OnQ Features
4Stream and navigate live slides
4Built in polling
4Send questions to the moderator
4Take notes by slides
4Complete surveys
4Access electronic course manuals
4Provide summary reports to clients by slide
or by participant
+Improve interactivity and data collection!
Our user interface is
designed based on
participant feedback
so it is intuitive
and easy-to-use.
Slides display in real-time
as presented, but can be
navigated forward and
backward through the
presentation.

ARRAY OnQ Features
4Built in polling
4Complete surveys
or by participant
Can you navigate forward and
backward through the live slides
being shown?
Real-time Questions:
Attendees can
ask questions while
the meeting is in
progress. Presenters
will see it on their
display.

ARRAY OnQ Features
4Built in polling
4Complete surveys
or by participant
Contact EM about our next
meeting!
ValuedClient@meeting.com
ARRAY OnQ
enables users to take
notes – either by
typing, or by writing
or drawing with
a stylus

Polling:
Ask questions at
any time during a
presentation. Attendees
respond by simply
tapping their choice.
“The Add-on Impact of Mobile Applications in Learning Strategies: A
Review Study” states that infusing iPads in the live learning environ-
ment is fundamentally changing the ability of faculty to engage par-
ticipants, increase interactivity, and improve efficiency in learning. A
recent study found that mobile technologies such as iPads have:
= Increased participant engagement in learning
= Enabled collaborative learning
= Increased productivity and efficiency during learning
= All of the above
Polling Question #1

“The Add-on Impact of Mobile Applications in Learning Strategies: A Review Study” states that
infusing iPads in the live learning environment is fundamentally changing the ability of faculty
to engage participants, increase interactivity, and improve efficiency in learning. A recent study
found that mobile technologies such as iPads have:
1. Increased participant engagement in learning
2. Enabled collaborative learning
3. Increased productivity and efficiency during learning
4. All of the above
Polling results
can be displayed
immediately.
Polling Question #1: Result

Conduct surveys
and evaluations
at any time. Data
collected is
compatible with
our analytics
application.
Survey

Presenter Bios
Christina Yieh
Science Director
Tellent Labs, Inc.
Christina Yieh has been Science Director for Tellent Labs since 2011.
Tellent is a world leader in microbiobial and genetic research with
over 20 years of funded experience, working closely with 11 major universities and research
institutions.
Christina Yieh joined the company in 2008 and worked in a variety of positions in the US and
in the UK. In 2009, she went to Paris, France as Science Development European Lead, manag-
ing global research programs. She returned to New York in May 2011 as Science Director and
since managed the development and launch of the division’s research paths.
Prior to joining Tellent, Yieh worked at PharMeta as a Science and lab lead. She received a
Masters of Science from Columbia University, New York and a Bachelors degree in Biology
from John Cabot International College in Rome, Italy.
Add all
of your pertintent
meeting information
with our flexible
tab system.

Participants can
rate each slide and
the results can be
viewed in the final
engagement report.
Tabs can be added
and customized to
suit your needs.

Engagement Report:
By-slide summary reports
help you track particpation
and effectiveness.
Includes all notes
taken and questions
asked by slide.

Additional Reports:
ARRAY OnQ offers
you a wide range of
additional in-depth reports.
genda Morning 1130
Vij sburstei@yahoo.com 2014-‐06-‐21
10:53:53 Will
a
pt
who
has
failed
post
transplant
maintenance
revlimid
qualify
for
the
anti
cd38
trial?
genda Morning 1130
Vij syed.huq@mercy.net 2014-‐06-‐21
11:09:31 For
pts
with
17p
del
is
Ibrutinib
a
reasonable
option
in
the
first
line
setting
genda Morning 1130
Vij axs2115@bjc.org 2014-‐06-‐21
11:09:50 Do
you
consider
gazyva
as
a
first
line
standard
of
care
now?
genda Morning 1130
Vij ahusain01@hotmail.com 2014-‐06-‐21
11:11:20 Comment
about
ideally
sib
in
cll
genda Morning 1130
Vij sburstei@yahoo.com 2014-‐06-‐21
11:11:57 Ibrutinib
in
myeloma?
genda Morning 1130
Vij bethany.sleckman@mercy.net2014-‐06-‐21
11:12:36 How
do
you
assess
response
to
ibrutinib
in
CLL,
especially
in
patients
without
lymphadenopathy?

genda Morning 1130
Vij jcarden@hsillc.com 2014-‐06-‐21
11:13:12 In
cll
with
17p
deletion
will
you
combine
ibrutinib
with
rituxan
genda Morning 1130
Vij mary@marymuscato.com 2014-‐06-‐21
11:13:42 Heard
about
PTH
PR.
Not
regular
PTH
causing
huge
hypercalcemia
in
CLL?

I
have
a
pt
w/
stag.
O
CLL.

Neg
for
cd38.

genda Morning 1130
Vij jcarden@hsillc.com 2014-‐06-‐21
11:20:09 Does
the
rituxan
clean
the
circulating
lymphocytes
genda Morning TITLE
SLIDE karl.king@ncmc-‐hospital.com2014-‐06-‐21
08:28:47 How
to
follow
with
PETi
when

CMS
has
limited
a
total
of
3
PET
per
diagnosis
per
life
time?
genda Morning TITLE
SLIDE axs2115@bjc.org 2014-‐06-‐21
09:55:25 Is
zytiga
just
a
less
toxic
ketoconazole
essentially?
genda Morning TITLE
SLIDE dr.liana.makarian@ozarksmedicalcenter.com2014-‐06-‐21
09:56:23 What
was
the
median
age
for
trial
combining
taxotere
and
ADT.
genda Morning 9:10
-‐
Carson syed.huq@mercy.net 2014-‐06-‐21
08:46:04 How
do
oncologists
balance
responsibility
to
individual
patients
vs
responsible
stewardship
of
healthcare
costs
or
is
that
even
the
responsibility
of
the
indiv
genda Morning 9:10
-‐
Carson jmuscato@gmail.com 2014-‐06-‐21
08:54:00 Comment
re
hospitalization
of
NSCLC
patients:
a
lot
get
admitted
for
exacerbation
of
COPD.
These
patients
may
have
had
worse
overall
PS
to
begin
with.
Al
genda Morning 9:10
-‐
Carson karl.king@ncmc-‐hospital.com2014-‐06-‐21
08:56:57 Abst.
6519:
Is
it
possible
that
pts.
on
clinical
trials
are
watched
more
closely
than
real
world
pts.
so
most
neutropenic
fever
are
taken
care
of

earlier?
genda Morning 9:10
-‐
Carson arifbari2000@yahoo.com 2014-‐06-‐21
08:59:34 Could
you
comment
on
surveillance
imaging
on
non
small
cell
lung
cancer,
frequency
and
length
of
imaging,
and
CT
vs
PET??
genda Morning 9:10
-‐
09:00:33 Previous
Asb.
8502
showed
benefit
for
PET/CT
for
prediction
of
PRS

OS.
Since
CMS
has
limited
a
total
PET
of
3
per
diagnosis
per
life
time,
any
recommend
genda Morning 9:10
-‐
Carson jmuscato@gmail.com 2014-‐06-‐21
09:03:15 How
does
Watson
decide
if
those
12M
pages
are
really
valid
or
good
studies?

genda Morning 9:10
-‐
Carson medicusaf4@att.net 2014-‐06-‐21
09:04:44 Explosion
of
oncology
meds,
treatments
-‐
I
need
Watson
IBM
Now,
how
do
I
sign
up??
genda Morning 9:10
-‐
09:09:28 ASb.
6513:
is
it
possible
the
30%
of
stage
III
colon
pts.
Who
did
not
receive
FOLFOX
x
12
due
to

surgical
complications
/
bowel
obstruction,
those
pts.
Died
o
genda Morning 8:30
-‐
Bartlett lgiannone@aol.com 2014-‐06-‐21
07:53:17 What
maintenance
rituxan
schedule
do
you
recommend
genda Morning 8:30
-‐
Bartlett jmuscato@gmail.com 2014-‐06-‐21
08:20:25 Do
those
FL
patients
with
a
positive
PET
reflect
the
possibility
of
some
large
cell
components
vs.
just
response
to
therapy?
Re
8502
genda Morning 8:30
-‐
Bartlett dr.liana.makarian@ozarksmedicalcenter.com2014-‐06-‐21
08:20:46 Does
it
mean
that
pet
negative
follicular
lymphoma
after
induction
does
not
need
maintenance
rituxan?

genda Morning 8:30
-‐
Bartlett syed.huq@mercy.net 2014-‐06-‐21
08:23:37 In
pts
with
negative
pet
post
tax,
can
you
skip
maintenance
rituxan
since
OS
better
than
PRIMA
genda Morning 9:50
-‐
Picus jmaheshwari@yahoo.com 2014-‐06-‐21
09:21:30
Is
weekly
taxotere
is
equally
effective
and
better
tolerated?
genda Morning 9:50
-‐
Picus jward2@dom.wustl.edu 2014-‐06-‐21
09:25:41 Will
the
early
data
on
the
use
of
taxotere
in
the
first
line
setting
in
high
volume
disease
change
your
clinical
practice?
genda Morning 9:50
-‐
Picus medicusaf4@att.net 2014-‐06-‐21
09:48:26 Discordance
between
12-‐core
prostate
biopsy
and
radical
prostatectomy
specimen.

I
have
seen
many
radically
removed
prostates
with
a
very
tiny
focus
of
genda Afternoon 1540
Wartman karl.king@ncmc-‐hospital.com2014-‐06-‐21
15:27:29
I
have
a
recent
patient
presented
with
diagnosis
of
Sebaceous
carcinoma
of
the
(R)
facial/
mandibular
area

sebaceous
adenoma
of
abdominal
wall
are
(1)
Please
explain
the
prevalence
of
pleomorphism
in
the
setting
of
Muir
Torre
syndrome;
(2)
What
is
the
clinical
significance
of
pleomorphism
for
my
patient

his
family
members?
genda Afternoon 2:00
-‐
Sorscher
NEW jmaheshwari@yahoo.com 2014-‐06-‐21
13:38:45 When
we
will
use
neuadjuvant
folfox
in
locally
advanced
rectal
cancer
before
chemo
radiation?
-‐
Sorscher
NEW syed.huq@mercy.net 2014-‐06-‐21
13:42:49 Should
we
be
recommending
multigene
panels
which
many
companies
are
marketing
for
hereditary
cancers,
given
the
ls
pts
carrying
brca
mutations?
-‐
Sorscher
NEW jward2@dom.wustl.edu 2014-‐06-‐21
13:46:41 You
make
a
case
for
resection
of
the
primary
tumor
in
CRC
in
the
modern
era.

Shouldn't
we
do
a
randomized
clinical
trial?
-‐
Sorscher
NEW gajera@hotmail.com 2014-‐06-‐21
13:47:33
When
to
have
surgery
for
primary
in
metastatic
colon
cancer
.?
Before
chemo
?
-‐
Sorscher
13:49:05
Natural
history
of
stage
4
colon
cancer

Surgery
7-‐8
months
Fu
add
6
weeks
iFL
17
Folfox
avast
in
24-‐30
months
How
can
surgery
patient
will
be
longer?
-‐
Sorscher
NEW jward2@dom.wustl.edu 2014-‐06-‐21
13:55:20 EORTC
22921
concluded
that
adjuvant
chemotherapy
is
unnecessary
in
patients
with
rectal
cancer
who
received
per
operative
chemo
radiotherapy.

Is
ther
-‐
Sorscher
NEW ahusain01@hotmail.com 2014-‐06-‐21
13:56:17 What
is
maxim
permissible
time
for
starting
adjuvant
-‐
Sorscher
13:59:47 Isnt
a
200
pt
study
underpowered
to
detect
a
difference
in
stage
2
colon
pts
for
folfox,
since
recurrence
rate
is
6%
-‐
Sorscher
NEW sburstei@yahoo.com 2014-‐06-‐21
14:00:16
Stage2msi
high
oxali
alone?
-‐
Linette jward2@dom.wustl.edu 2014-‐06-‐21
11:59:14 It
has
been
thought
that
immune
therapy
like
ipilimumab
is
more
effective
when
disease
is
present
to
prime
the
immune
system,
does
the
adjuvant
data
as
-‐
Linette axs2115@bjc.org 2014-‐06-‐21
11:59:16 Do
you
think
eortc
9008
should
have
used
High
dose
IFN
as
standard
arm
instead
of
placebo
against
ipilimumab?
-‐
Linette jcarden@hsillc.com 2014-‐06-‐21
12:00:43 Does
Ipilimumab
should
replace
interferon
in
adjuvant
therapy
of
stage
III
melanoma
?
-‐
Linette lgiannone@aol.com 2014-‐06-‐21
12:03:28 What
is
the
role
of
IL-‐2
in
metastatic
melanoma
-‐
Linette jcarden@hsillc.com 2014-‐06-‐21
12:17:52 What
is
yours
first,
second,
etc.
line
therapy
for
metastatic
malignant
melanoma?

-‐
Linette axs2115@bjc.org 2014-‐06-‐21
12:22:10 Are
kras
and
Nras
mutations
mutually
exclusive?
-‐
Linette syed.huq@mercy.net 2014-‐06-‐21
12:25:09 Still
a
role
for
chemo
with
carbo-‐taxol+Bev
without
braf
mutation?
-‐
Morgensztern
NEW rvij@dom.wustl.edu 2014-‐06-‐21
12:38:47 Is
Brazil
going
to
win
the
World
Cup?
-‐
Morgensztern
12:49:17 After
this
PCI
study
would
you
offer
PCI?
-‐
Morgensztern
NEW karl.king@ncmc-‐hospital.com2014-‐06-‐21
12:51:26 PCI
dose
of
25
Gy
in
10
fx.
is
too
low
.
The
radiobiological

equivalent
of
only
30Gy
with
standard
fractionation
equivalent
of
40Gy.
-‐
Morgensztern
13:00:30 The
CREST
trial
design
is
flawed
because
the
radiation
dose
is
inadequate!
30
Gy
is
only
an
adequate
dose
for
a
quick
palliation.
If
one
wants
to
truly
evalua
-‐
Morgensztern
NEW axs2115@bjc.org 2014-‐06-‐21
13:07:50 Does
afatinib
have
activity
in
egfr
mutant
patients
second
line
after
erlotinib?
How
about
in
t790
mutants
activity
of
afatinib?
-‐
Morgensztern
NEW mmeadors@sfmc.net 2014-‐06-‐21
13:08:15 Management
strategy
for
EGFR
mutant
patient
progressing
on
Tarceva.
-‐
Morgensztern
13:08:16
For
pts
with
t790m
mutations,
would
you
use
the
3rd
line
agents
in
the
upfront
setting?
If
not
available

,chemo
or
afatinib.
-‐
Morgensztern
13:14:40 The
design
of
the
trial
is
flawed.
It
should
be
to
evaluate
the
extensive
disease
who
has
a
CR
after
chemo
radiation
,
not
any
response.
If
patients
have
per
-‐
Morgensztern
13:20:31 Dr.
Morgen
stern
,
if
you
want
to
ask
a
radiation
oncology
question,

you
should
ask
your
Radiation
Oncology
colleagues
at
MIR.
Radiation
therapists
are
the
Wang-‐Gillam karl.king@ncmc-‐hospital.com2014-‐06-‐21
14:49:48 I
assume
in
the
ARTIST
trial
the
total
dose
of
X
rat
is
4500
cGy
not
45
cGy
as
on
the
side.
Please
correct.
Wang-‐Gillam jcarden@hsillc.com 2014-‐06-‐21
14:55:11 What
was
the
schedule
and
doses
of
the
ruxolitinib
when
use
Vs
placebo?
Wang-‐Gillam jcarden@hsillc.com 2014-‐06-‐21
14:56:34 What
was
the
schedule
and
doses
of
the
ruxolitinib
when
use
Vs
placebo?

(Single
agent)

Questions SubmittedAttendee Registration
Activities used in this report:Activities used in this report:Activities used in this report:Activities used in this report:
Review
of
the
Presentations
from
the

ASCO
2014
Annual
MeetingReview
of
the
Presentations
from
the

ASCO
2014
Annual
MeetingReview
of
the
Presentations
from
the

ASCO
2014
Annual
MeetingReview
of
the
Presentations
from
the

ASCO
2014
Annual
Meeting
Intervals used in this report:Intervals used in this report:Intervals used in this report:Intervals used in this report:
Pre
Post
Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?Denes 1 - Which best describes your clinical practice?
Answer Pre Pre
% Post Post
%
pure
hematology
(benign
and
malignant) 0 0 0 0
mostly
hematology
with
occasional
solid
tumors 5 11 0 0
Mostly
general
solid
tumor
oncology
with
some
hematology29 63 0 0
General
solid
tumor
oncology
(more
than
5
disease
types)7 15 0 0
Disease
focused
solid
tumor
oncology
(
5
disease
types
or
less)5 11 0 0
Total 46 100% 0 100%
Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?Denes 2 - Which best reflects your feelings about the rapid expansion of “targeted” therapies in oncology?
Answer Pre Pre
% Post Post
%
The
number
of
new
agents
is
overwhelming
and
I
cannot
keep
up
with
the
new
agents11 23 0 0
The
number
of
new
agents
is
challenging
but
I
feel
comfortable
and
use
all
of
them21 45 0 0
The
number
of
new
agents
is
challenging,
so
I
have
limited
my
use
to
a
few
selected
agents15 32 0 0
Total 47 100% 0 100%
Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?Denes 3 - How have you incorporated immune modulating agents into your practice?
Answer Pre Pre
% Post Post
%
I
feel
comfortable
with
them
and
have
used
them
in
my
practice31 66 0 0
I
feel
comfortable
with
them
but
prefer
not
to
use
them
in
my
practice4 9 0 0
I
do
not
feel
comfortable
with
them
and
do
not
use
them
in
my
practice12 26 0 0
Total 47 100% 0 100%
Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?Denes 4 - You are referred a 55 year old man with newly diagnosed V600E mutated metastatic melanoma with extensive lung, liver , and bone metastases. Which of the following would you recommend?
Answer Pre Pre
% Post Post
%
Single
agent
ipilimumab 6 13 0 0
Single
agent
vemurafenib 9 19 0 0
Combination
of
trametinib
and
dabrafenib 11 23 0 0
Combination
of
ipilumumab
and
vemurafenib 3 6 0 0
Refer
patient
to
melanoma
expert
for
management19 40 0 0
Total 48 100% 0 100%
0
17.5
35
52.5
70
pure
hematology
(benign
and
malignant) General
solid
tumor
oncology
(more
than
5
disease
types)
00000
11
15
63
11
0
Which
best
describes
your
clinical
practice?
%
Pre
%
Post
%
0
12.5
25
37.5
50
The
number
of
new
agents
is
overwhelming
and
I
cannot
keep
up
with
the
new
agents
000
32
45
23
Which
best
reflects
your
feelings
about
the
rapid
expansion
of
“targeted”
therapies
in
oncology?
%
Pre
%
Post
%
0
17.5
35
52.5
70
I
feel
comfortable
with
them
and
have
used
them
in
my
practice I
do
not
feel
comfortable
with
them
and
do
not
use
them
in
my
practice
000
26
9
66
How
have
you
incorporated
immune
modulating
agents
into
your
practice?
%
Pre
%
Post
%
0
10
20
30
40
Single
agent
ipilimumab Combination
of
trametinib
and
dabrafenib Refer
patient
to
melanoma
expert
for
management
00000
40
6
23
19
13
You
are
referred
a
55
year
old
man
with
newly
diagnosed
V600E
mutated
metastatic
melanoma
with
exten
%
Pre
%
Post
%
Polling Results

Additional
Features
ServicesReduce Costs
Data Compatibility EM Customer Service
Bundled Services
EM offers a complete range
of event services including
full service A/V. Ask about
how you can save by
bundling services.
ARRAY OnQ helps
you beat high printing costs by
making materials available in
digital form, and giving you the
flexibility to make last minute
changes to content.
Make the most of
your collected data
by importing
into our ARRAY
Analytics tool.
Our highly skilled
on-site service team
is always there to
ensure your event
is perfect.
A / V , A R S , a n d M o r e
ARRAY Analytics

educationalmeasures.com
Would you
like to see
more?
If you would like to arrange
a demo, or drop in on a live
event to see ARRAY OnQ in
action, let us know – We’d
love to work with you!
303-952-1535
mgarcia@educationalmeasures.com

Em Array - Interactive Meeting Technology

Recomendados

Recomendados

Más contenido relacionado

Similar a Em Array - Interactive Meeting Technology

Similar a Em Array - Interactive Meeting Technology (20)

Último

Último (20)

Em Array - Interactive Meeting Technology